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Abstract
Background: Controversy exists regarding the optimal treatment for patients with displaced intracapsular fractures
of the proximal femur. The recognised treatment alternatives are arthroplasty and internal fixation. The principal
criticism of internal fixation is the high rate of non-union; up to 30% of patients will have a failure of the fixation
leading to revision surgery. We believe that improved fracture healing may lead to a decreased rate of failure of
fixation. We therefore propose to investigate strategies to both accelerate fracture healing and improve fixation
that may significantly improve outcomes after internal fixation of intracapsular femoral fractures. We aim to test the
clinical effectiveness of the osteoinductive agent platelet rich plasma and conduct a pilot study of a novel fixed-
angle fixation system.
Design: We have planned a three arm, single centre, standard-of-care controlled, double blinded, pragmatic,
randomised clinical trial. The trial will include a standard two-way comparison between platelet-rich plasma and
standard-of-care fixation versus standard-of-care fixation alone. In addition there will be a subsidiary pilot arm
testing a fixed-angle screw and plate fixation system.
Trial Registration: Current Controlled Trials ISRCTN49197425
Background
Epidemiology
Proximal femoral fractures are one of the greatest chal-
lenges facing the medical community. In 1990, a global
incidence of 1.31 million was reported and was asso-
ciated with 740,000 deaths [1]. Proximal femoral frac-
tures constitute a heavy socioeconomic burden
worldwide. The cost of this clinical problem is estimated
at 1.75 million disability adjusted life years lost, 1.4% of
the total healthcare burden in established market econo-
mies [1].
Existing knowledge
Proximal femoral fractures can be subdivided into intra
and extracapsular fractures. Approximately half of all
proximal femoral fractures are intracapsular. These frac-
tures are at risk of healing complications as the blood
supply to the femoral head may be compromised by the
fracture. There are two operative strategies in the man-
agement of intracapsular fractures of the proximal
femur: internal fixation and hip arthroplasty.
Arthroplasty surgery eliminates the risk of fixation
failure as the femoral head is replaced. However, it is a
major operation with very significant complications of
its own including infection, dislocation and peripros-
thetic fracture. The most common form of arthroplasty
in this group of patients is hemiarthroplasty, where the
head of the femur is replaced but the acetabulum is
left intact, but this procedure is associated with an
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to arthritic changes and the potential need for further
surgery [2]. Internal fixation has the key advantage of
preserving the patients’ own bone and cartilage. It is
also a quicker operation requiring a much smaller
wound. The principal complication of internal fixation
is non-union which is related to the tenuous blood
supply to the femoral head. However, the rate of non-
union and fixation failure has been reported at up to
33%, [3] leading to re-operation in 90% of these
patients. Consequently, the best treatment of these
fractures remains controversial. A recent Cochrane
review [4] has confirmed that the evidence suggests
that there is no clinical benefit of one treatment over
the other.
In order for any fracture to heal successfully there
must be both a good biological environment and ade-
quate fracture fixation. When a fracture heals there is a
balance between the time required to achieve union and
the time over which the fixation maintains fracture posi-
tion. Therefore, the failure of a fracture to heal may be
due to an inadequate biological environment (leading to
a long healing time) or an inadequate fixation system
(leading to a short period of effective fixation). Interven-
tions to improve fracture healing are targeted at one of
these two broad areas. In patients with intracapsular
fractures of the proximal femur interventions to
improve fracture healing may reduce the rate of fixation
failure and therefore the requirement for major arthro-
plasty surgery.
Aim of the trial
The aim of this trial is to investigate the clinical effec-
tiveness of novel surgical interventions to improve clini-
cal outcomes following fracture of the proximal femur.
Currently, there are two new techniques available which
have shown promising early results for the treatment of
acute fractures: firstly, platelet-rich plasma (PRP) which
is an autologous source of growth factors derived from
ap a t i e n t ’s whole blood; secondly, novel fixed-angle
screw and plate systems which are available following
developments in the field of fragility fracture fixation.
Early results of both these interventions are promising
but there is no Level I clinical data [5,6].
Hypothesis
We propose to test the hypotheses that: PRP leads to a
reduced incidence of failure of fixation in patients with
intracapsular fractures of the proximal femur.
We propose to explore the size of any treatment effect
due to a novel fixed-angle screw and plate system in the
treatment of patients with intracapsular fractures of the
proximal femur.
The need for a trial
A review [4] from The Cochrane Database for Systema-
tic Reviews 2007 states:
“Fractures of the thigh bone (femur) near the hip joint
(termed intracapsular) may be treated by fixing the
f r a c t u r e( w i t hs c r e w so rp i n s ) ,o ra l t e r n a t i v e l yr e p l a -
cing the top of the femur at the hip joint (femoral
head) with an artificial hip joint (arthroplasty). This
review found that each treatment has its own specific
complications. Realigning the bones and fixing the
fracture (reduction and internal fixation) is a shorter
operation with less blood loss, but is more likely to
need a second operation (36% versus 11%). The rea-
son for this is mainly from a failure of the bone to
heal in those cases treated with fixation. Internal fixa-
tion is associated with less initial operative trauma
but has an increased risk of re-operation on the hip.”
A search of the national and international clinical
trials databases has revealed that there is only one other
trial that is being carried out in the USA [7]. This is a
commercial trial assessing the use of bone morphoge-
netic protein (BMP) only. A commercial trial in Leeds,
UK investigating the effect of BMP in proximal femoral
fractures has recently been abandoned. Otherwise there
is no high quality clinical research in this field.
Good Clinical Practice
The trial will be carried out in accordance with Good
Clinical Practice (GCP) and in accordance with the fol-
lowing protocol.
CONSORT recommendations
The trial will be reported in line with the CONSORT
statement [8].
Methods
Trial Design
Design summary
This trial will be a three arm single centre, standard-of-
care controlled, double blinded, pragmatic, randomised
clinical trial.
The study will include a standard two-way comparison
between PRP and standard-of-care fixation versus stan-
dard-of-care fixation alone. This comparison will be the
only hypothesis-testing analysis. In addition there will be
a subsidiary pilot arm testing fixed-angle screw and
plate fixation. This comparison will be a hypothesis-
generating analysis only.
The trial is expected to last a total of two years. It is
expected that participant recruitment will take one year
and final follow-up will be at one year.
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Objectives of the trial
The objectives of this trial are to:
1. test the hypothesis that PRP leads to a reduced
incidence of failure of fixation.
2. explore the size of any treatment effect of a novel
fixed-angle screw and plate fixation system
Measures of efficacy
Primary ￿ The proportion of participants undergoing
re-operation for failure of fixation within one year of
sustaining the fracture.
Secondary ￿ Radiographic non-union rate at 12 months.
Non-union will be defined as “failure of the fracture
to show signs of bony union on the anteroposterior
or lateral radiograph 1 year after surgery” [9].
￿ Radiographic evidence of failure of fixation at 6, 12
and 52 weeks
￿ Radiographic evidence of avascular necrosis at one
year
￿ Magnetic resonance imaging at 6, 12 and 52 weeks.
This measure will only be recorded for those partici-
pants with capacity.
￿ The EQ-5D score at 6, 12 and 52 weeks
￿ Length of index hospital stay
Measures of harm and adverse events
Expected Adverse Events ￿ Wound infection
￿ Venous thrombo-embolic phenomena
￿ Death
￿ Pneumonia
￿ Urinary tract infection
￿ Blood transfusion
￿ Failure of fixation
￿ Cerebrovascular accident
￿ Acute coronary syndrome
￿ Myocardial infarction
￿ Deep vein thrombosis
Power and sample size
The minimum clinically important treatment effect of
PRP was agreed in discussion with several expert ortho-
paedic trauma surgeons. Although the figures varied by
surgeon, all agreed that an absolute reduction of 15% in
fixation failure would be clinically important. The
overall rate of fixation failure of all intracapsular frac-
tures of the femur is reported to be 20-35% [10]. Table
1 shows the total sample size with two-sided signifi-
cance set at 0.05 for various scenarios of minimum
clinically relevant difference. Sample sizes were deter-
mined using the PS power and sample size software
[11].
The mortality of patients with intracapsular fractures
of the proximal femur is approximately 20% during the
first year and this needs to be taken into account in the
sample calculation. A recruitment target of 200 partici-
pants provides a good margin for unanticipated recruit-
ment problems and loss to follow-up.
In the absence of an agreed method to determine the
sample size for a pilot study a group of expert orthopae-
dic surgeons were consulted. All agreed that a sample of
25 participants in the fixed-angle screw and plate group
would be sufficient to provide adequate pilot data.
From a recent audit carried out in our department we
know that approximately 450 fractures of the proximal
femur are treated operatively per year at University Hos-
pital Coventry and Warwickshire. Approximately 250 of
these patients would be eligible for inclusion into this
trial. Therefore, even accounting for significant loss to
follow-up, the trial sample can be recruited in one year.
Eligibility
Inclusion criteria In order that the results of this ran-
domised clinical trial can be generalised as widely as
possible, we propose to include all patients, including
those with cognitive impairment, admitted with an
intracapsular (displaced or undisplaced) fracture of the
proximal femur. This pragmatic approach will mean
that any conclusions derived will be widely applicable to
clinical practice.
Exclusion criteria ￿ All patients who present late fol-
lowing their injury i.e. more than 48 hours after the
index fracture.
￿ Patients with other serious injuries to either lower
limb that would interfere with rehabilitation of the
index fracture.
￿ Patients who are managed non-operatively
Post-randomisation withdrawals and exclusions
Participants may withdraw from the trial treatment and/
or the whole trial at any time without prejudice. If a
Table 1 Sample sizes calculated for various scenarios
Rate of failure in control group (%) Rate of failure in the intervention group (%)
10 15 25
80% power 90% power 80% power 90% power 80% power 90% power
25 100 133
30 62 82 121 161
35 43 57 73 97 329 440
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followed-up wherever possible and data collected until
the end of the trial.
The General Practitioners of those participants who
are “lost-to-follow-up” will be contacted in order to
attempt to complete the follow-up. Failing this then the
Hip Fracture Register will be consulted in order to try
to establish up-to-date participant contact details. Parti-
cipants may be withdrawn from the trial at the discre-
tion of the Chief Investigator due to safety concerns.
Consent
An informed consent discussion will be conducted with
potential participants after eligibility checks have been
performed but prior to randomisation.
Potential participants will be informed about the nat-
ure of the trial by the investigator or persons designated
by the investigator. This will involve a discussion of pur-
pose and requirements of the trial and the issuing of the
participant information sheet.
Patients will be allowed, where possible, at least
twenty four hours to consider the information given
them prior to being asked to give informed consent to
participate in the trial. This period of time will not be
allowed to delay any normal standard of care treatment.
Responsibility for recording and dating both verbal
and written, signed informed consent will be with the
investigator, or persons designated by the investigator,
who conducted the informed consent discussion. The
following information will be discussed during the con-
sent discussion:
￿ Benefits of internal fixation of intracapsular proxi-
mal femoral fractures
￿ Risks of internal fixation of intracapsular proximal
femoral fractures
￿ Impact of allocation to different treatment arms of
the trial
￿ Requirements of follow-up
￿ Benefits of taking part in the trial
For those patients who lack the capacity to give
informed consent reasonable efforts will be made to
identify a Personal Consultee as described in the Mental
Capacity Act 2005. If no personal consultee can be iden-
tified then a Nominated Consultee will be nominated to
advise the research team. The following persons will be
approached in the order given in the list below:
i. The patient’s General Practitioner
ii. Mr Wade FRCS(Tr&Orth), Consultant Orthopae-
dic Surgeon UHCW.
At all times the Chief Investigator will act in accor-
dance with the patients’ best interests.
Recruitment
Participant recruitment will begin in August 2009 and
be completed by August 2010. Pre-randomisation elig-
ibility checks will be carried out to ensure that partici-
pants are not randomised in error, and informed written
consent will be obtained prior to randomisation. Confir-
mation of these checks will be carried out by the investi-
gator, or persons designated by the investigator, prior to
randomisation. Inclusion of the patient in the trial will
be flagged on their clinical notes by means of a trial
sticker.
Treatment allocation
Sequence generation The allocation sequence will
be generated randomly. The randomisation will be
weighted such that at the end of the trial there will be
25 participants in the fixed-angle screw and plate
group and 100 participants in each of the remaining
groups. Randomisation will be stratified by displace-
ment of the fracture. Fractures will be defined as
undisplaced (Garden grade I or II) or displaced (Gar-
den grade III or IV); Garden’s classification of intra-
capsular fractures is well recognised and universal and
it has been validated to distinguish between grades I
a n dI Ic o m p a r e dw i t hI I Ia n dI V[ 1 2 , 1 3 ] .T h es u r g e r y
will be performed by any of the 16 Consultant Sur-
geons, two Associate Specialists and 14 Trainees at the
University Hospital Coventry and Warwickshire. The
large number of surgeons and the wide skill mix
should eliminate the ‘surgeon effect’ such that stratifi-
cation by surgeon is not required.
Allocation concealment The allocation sequence will be
generated using secure, online randomisation via a dis-
tant computer generated system administered by The
University of York.
Allocation implementation Participants will be enrolled
by the trial research associates, co-ordinated by Mr
Xavier Griffin. Participants will be assigned to their
treatment allocation at the time of surgery by accessing
the online randomisation programme. This will allow
for treatment allocation to be implemented outside of
working hours.
Blinding
Participants will be blinded to the treatment allocation.
The operating surgeon will not be blinded to the alloca-
tion. All outcomes will be assessed by blinded assessors.
The primary outcome measure will be determined by
the clinical decision of the responsible consultant ortho-
paedic surgeon who is independent from the trial. The
responsible consultant surgeon will not be the operating
surgeon in order to maintain the blind. The EQ-5D is a
patient reported measure. Patients will be kept blinded
until the completion of the trial when the blind is bro-
ken. Radiographic outcomes will be assessed by an inde-
pendent consultant radiologist who is blinded to the
Griffin et al. BMC Musculoskeletal Disorders 2010, 11:184
http://www.biomedcentral.com/1471-2474/11/184
Page 4 of 8treatment allocation. There will be no formal analysis of
the success of the blinding.
Trial treatments
All participants will have a closed reduction of their
fracture. The lower limb will be supported on a fracture
table. Internal fixation of the fracture will be achieved
through a standard lateral approach with perioperative
antibiotic cover in accordance with hospital protocol.
Post-operative care will include early active mobilisation
managed by a standard physiotherapy rehabilitation
regime. All participants will have routine prophylaxis
against deep vein thrombosis. Participants will be rando-
mised to one of three groups:
1. Fixed-angle screw and plate fixation
2. Standard of care fixation and placebo injection
3. Standard of care fixation and PRP injection
Group 1: Fixed-angle screw and plate fixation
Fixation will be with the Targon FN Head Preserving
System as described in the manufacturer’so p e r a t i v e
technique manual.
Group 2: Standard of care fixation
Fixation will be with three parallel cannulated screws.
The exact configuration will be left to the discretion of
the operating surgeon to ensure the results can be easily
generalised. Fixation will be achieved using the standard
operative technique.
Group 3: Standard of care fixation and PRP injection
Fixation will be with three parallel cannulated screws.
The exact configuration will be left to the discretion of
the operating surgeon to ensure the results can be easily
generalised. Each screw will be advanced up to but not
beyond the fracture such that no compression is
achieved before the test substance is injected. The
guidewire of one screw will then be removed and 5ml of
PRP will be injected down the cannulated screw directly
into the fracture site under image intensifier guidance.
The guidewire will be immediately replaced and the
screw/s will then be advanced to compress the fracture
site.
Concomitant illnesses and medication
Concomitant illnesses and medication will be recorded
at trial entry. Changes to these will be recorded at fol-
low-up visits.
Interventions and assessments
Table 2 details the assessments and interventions that
will be carried out during the period that each partici-
pant is involved in the trial.
End of the trial
The trial will be closed when all participants have com-
pleted the one year follow-up visits. Once the trial is
completed participants will be treated as per the stan-
dard of care.
Trial Flow diagram
See figure 1.
Data management
Database and data management
Data to be collected from participants can be found at
table 3. These data will be entered in the trial database.
The trial database will be set up by the computer pro-
grammer and all specifications agreed between the com-
puter programmer, statistician and trial co-ordinator.
T h ep r o c e d u r ef o rd a t ae n t r yw i l lb ed e c i d e dw h e nt h e
database is constructed. If electronic databases are
required on computers external to the clinical trials
u n i t ,t h e yw i l lb ec o m p a t i b l ew i t ht h es y s t e m so ns i t e
and backed-up accordingly. In the case of any interim
analysis the database will be frozen at the analysis time
point. Data collected after this point will not be included
in the interim report.
The case report forms will be designed by the Trial
Co-ordinator in consultation with the Chief Investigator
and statistician.
In the event of missing data the relevant clinical data-
bases and case report forms will be accessed to com-
plete the database.
Data access and quality assurance
All data collected will be anonymised after the collection
of the baseline demographic data for each participant.
Identifiable participant data will be held on a separate
database and coded with a trial participant code to tag
identifiable data to the outcome data.
All data will be stored in a designated storage facility
in the Clinical Sciences Building on the research site at
the University of Warwick. Data will be stored on pass-
word protected university computers in a restricted
access building.
Archiving of trial data
Data will be archived in accordance with The University
of Warwick clinical trials unit guidance.
Table 2 Trial assessments and interventions
Serial Intervention/Measurement Time (weeks)
1 Operation 0
Peri-operative complications
2 AP & lateral radiographs 6
MRI (subset of sample)
Clinical interview
3 AP & lateral radiographs 12
MRI (subset of sample)
Clinical interview
4 AP & lateral radiographs 52
MRI (subset of sample)
Clinical interview
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T h e r ew i l lb ead a t am o n i t o r ing committee convened
for this trial.
Statistical analysis plan
Analysis of efficacy
PRP vs standard-of-care (parallel cannulated screws)
The primary outcome measure, the proportion of
patients requiring re-operation for failure of fixation
within one year of sustaining the fracture, will be ana-
lysed using a chi-squared test for differences between
internal fixation alone (control) and internal fixation
and PRP (PRP) on an intention-to-treat basis. Treat-
ments will be considered to differ significantly if p-
values are <0.05 (5% level). Similarly, chi-squared tests
will be used to assess the significance of observed differ-
ences for the secondary proportional outcome measures.
If the numbers in the contingency tables are small (cells
Figure 1 Trial flow diagram.
Table 3 Data to be collected during the trial
Serial Intervention/Measurement Time (weeks)
1 Peri-operative complications 0
2 EQ-5D score 6
Radiographic union and fixation
Re-operation
Readmission
3 EQ-5D score 12
Radiographic union and fixation
Re-operation
Readmission
4 EQ-5D score 52
Radiographic union and fixation
Avascular necrosis
Re-operation
Readmission
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used in preference to the chi-squared test. In addition
to the main analysis, that will report treatment group
effects for the primary outcome measure, a subsidiary
analysis will use a multiple linear regression model to
investigate the relationship between each patient’sE Q -
5D Score at 12 months and the treatment arm, age, gen-
der, dementia and fracture displacement for each
patient. Estimates, and 95% confidence intervals, from
the regression model, and unadjusted results from t-
tests will be reported and inferences made on the signif-
icance of the treatment effect. All analyses will be based
upon an intention-to-treat analysis so missing data due
to protocol violations will not be relevant. The primary
outcome measure in this study has been chosen in
order to limit the possibility of losing data from failed
participant follow-up. The primary measure can be
sourced from the patient, relative, GP or national hp
fracture database.
Fixed-angle plate and screws vs standard-of-care
(parallel cannulated screws) No formal inference sta-
tistical analysis will be conducted on the data from the
pilot arm of the study. The proportional primary event
rate, mean estimates and variability of the secondary
measures in the two groups will be described. Addition-
ally an estimate of the size of the treatment effect due
to the fixed-angle plate will be made to inform further
study designs.
Subgroup analyses
Planned subgroup analyses will be undertaken only for
fracture displacement (displaced vs undisplaced),
dementia and appropriate age groups.
Analysis of adverse events
The number and temporal pattern of adverse events will
be investigated to assess if these differ between treat-
ment groups.
Trial organisation and oversight
Trial steering committee
A trial steering committee will be convened and inde-
pendently chaired in accordance with the University of
Warwick Clinical Trials Unit standard operating proce-
dures. In addition to the independent chair, Mr M
Costa, Mr X Griffin, Dr J Achten and Dr N Parsons will
form the committee. All issues pertaining to the man-
agement of the trial will be co-ordinated by the trial
steering committee. The schedule for meetings of the
committee will be as follows:
Meeting 1: Trial commencement
Meeting 2: Interim meeting at 50% recruitment
Subsequent meetings: End of trial
Data monitoring committee
A data monitoring committee will be convened once the
trial is 50% recruited. The committee will be chaired by
Mr S Drew, University Hospital Coventry and Warwick-
shire NHS Trust.
Trial registration
The trial is registered with the Current Controlled Trials
register ISRCTN49197425. The trial has been adopted
by the National Institute for Health Research Clinical
Research Network Portfolio NIHR CRN Study ID: 7762.
Project timetable and milestones
Trial recruitment commenced August 2009
All participants recruited August 2010
Trial completed August 2011
Trial reported December 2011
Unblinding
The blind will only be broken for clinical management
purposes. In exceptional circumstances beyond this
agreement will be sought from the Chief Investigator
and statistician before the blind is broken.
Interim analysis
There will be no formal interim analysis conducted.
Indemnity/compensation/insurance
All issues of indemnity, compensation and insurance are
detailed in the joint sponsorship agreement between the
University of Warwick and University Hospital Coventry
and Warwickshire NHS Trust.
Essential documents
All essential documentation will be stored as specified
under the guidance from the clinical trials unit.
Monitoring and quality assurance policy
The Chief Investigator and data entry technician will
conduct sampling of the database quarterly in order to
identify any problems in trial procedures.
Dissemination and publication
The results of this trial will be disseminated to the
trauma and orthopaedic surgery community via presen-
tations at national and international meetings as well as
publication in peer reviewed journals.
Financial support
The trial will be funded by the Furlong Research Chari-
table Foundation and the Bupa Foundation.
Acknowledgements
The authors would like to thank Dr Richard Wellings and Dr Sarah Wayte for
their generous help and expertise in developing appropriate MR imaging
protocols to assess fracture healing. We would also like to thank Professor
Damian Griffin for the support of his department in the preparation of this
trial protocol. This work was supported by the Furlong Research Charitable
Foundation and the Bupa Foundation (grant number TBF-RR10-001).
Authors’ contributions
XG and MC developed the trial concept and design. All authors made
significant contributions to the design, drafting and critical revision of the
Griffin et al. BMC Musculoskeletal Disorders 2010, 11:184
http://www.biomedcentral.com/1471-2474/11/184
Page 7 of 8trial protocol. XG will co-ordinate participant recruitment and follow-up. All
authors will be responsible for data interpretation and reporting of the trial.
All authors read and approved the final manuscript.
Competing interests
Gian Medical have agreed to provide the consumables for the production of
the platelet-rich plasma used in the treatment of some participants in this
trial.
BBraun have agreed to provide the Targon FN Head Preserving System used
in the treatment of some participants in this trial.
Neither Gian Medical nor BBraun have any rights to the intellectual property
generated from the data produced by this trial.
XG is funded by the Furlong Research Charitable Foundation to carry out
this research.
The trial is funded by a grant from the Bupa Foundation.
Received: 13 May 2010 Accepted: 17 August 2010
Published: 17 August 2010
References
1. Johnell O, Kanis JA: An estimate of the worldwide prevalence, mortality
and disability associated with hip fracture. Osteoporos Int 2004,
15(11):897-902.
2. D’Arcy J, Devas M: Treatment of fractures of the femoral neck by
replacement with the Thompson prosthesis. The Journal of bone and joint
surgery 1976, 58-B(3):279-286.
3. Lu-Yao GL, Keller RB, Littenberg B, Wennberg JE: Outcomes after displaced
fractures of the femoral neck. A meta-analysis of one hundred and six
published reports. The Journal of bone and joint surgery 1994, 76(1):15-25.
4. Parker MJ, Gurusamy K: Internal fixation versus arthroplasty for
intracapsular proximal femoral fractures in adults. Cochrane Database Syst
Rev 2006, 4:CD001708.
5. Griffin XL, Smith CM, Costa ML: The clinical use of platelet-rich plasma in
the promotion of bone healing: a systematic review. Injury 2009,
40(2):158-162.
6. Parker MJ: Preliminary results of a new dynamic locking plate and screw
system for intracapsular hip fractures. Injury Extra 2008, 39(5):200.
7. NCT00384358 Cg: A Phase 2, Multicenter, Single-Blind, Randomized,
Stratified, Standard-of-Care Controlled, Feasibility and Safety Study of
rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal
Femur. 2007.
8. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D,
F SK, Simel D, et al: Improving the quality of reporting of randomized
controlled trials. The CONSORT statement. JAMA 1996, 276:637-639.
9. Parker MJ, Raghavan R, Gurusamy K: Incidence of fracture-healing
Complications after Femoral Neck Fractures. Clinical Orthopaedics and
Related Research 2007.
10. Parker MJ, Khan RJ, Crawford J, Pryor GA: Hemiarthroplasty versus internal
fixation for displaced intracapsular hip fractures in the elderly. A
randomised trial of 455 patients. The Journal of bone and joint surgery
2002, 84(8):1150-1155.
11. Dupont W, Plummer D: PS: Power and Sample Size..
12. Garden RS: Low-Angle fixation in fractures of the femoral neck. The
Journal of bone and joint surgery 1961, 43:647-663.
13. Parker MJ: Garden grading of intracapsular fractures: meaningful or
misleading? Injury 1993, 24(4):241-242.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/11/184/prepub
doi:10.1186/1471-2474-11-184
Cite this article as: Griffin et al.: Warwick Hip Trauma Study: a
randomised clinical trial comparing interventions to improve outcomes
in internally fixed intracapsular fractures of the proximal femur.
Protocol for The WHiT Study. BMC Musculoskeletal Disorders 2010 11:184.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Griffin et al. BMC Musculoskeletal Disorders 2010, 11:184
http://www.biomedcentral.com/1471-2474/11/184
Page 8 of 8